Alternative Antiplatelet Therapy After TAVR When Clopidogrel is Not Tolerated

Primary Recommendation: Aspirin Monotherapy

The American College of Cardiology recommends aspirin 75-100 mg daily alone as the most appropriate alternative when clopidogrel cannot be tolerated in patients without other indications for anticoagulation 1, 2
The 2017 ACC Expert Consensus states that standard therapy is clopidogrel for 3-6 months plus lifelong aspirin, so if clopidogrel must be discontinued, continuing aspirin alone is the logical fallback 1, 2

Avoid adding additional antiplatelet agents beyond aspirin in patients with documented bleeding history 3, 4

Extended-release dipyridamole may be considered as an alternative antiplatelet agent, though this is based on stroke prevention data rather than TAVR-specific evidence 3, 4

Warfarin (INR 2.0-3.0) may be considered for the first 3 months post-TAVR in patients at risk for valve thrombosis, though this carries higher bleeding risk 1, 2
The American Heart Association and American College of Cardiology note that vitamin K antagonist therapy for 3-6 months after bioprosthetic valve replacement may be reasonable (Class IIb recommendation) 5, 6

Oral anticoagulation becomes mandatory if atrial fibrillation is detected, and should be used per AF guidelines for patients with prosthetic heart valves 1, 2, 7

Direct oral anticoagulants should NOT be used as routine alternatives in the absence of atrial fibrillation or other standard anticoagulation indications 6

Perform ECG monitoring periodically to detect asymptomatic atrial fibrillation, which would change anticoagulation strategy 1
Echocardiography at 30 days and annually to monitor for valve thrombosis and other complications 1

Do not use DOACs as a "safer" alternative to aspirin monotherapy without a clear indication like atrial fibrillation 6
Do not discontinue all antithrombotic therapy—aspirin monotherapy remains essential for lifelong use 1, 2

The American College of Cardiology recommends standard antithrombotic therapy after TAVR as clopidogrel 75 mg daily for 3-6 months plus aspirin 75-100 mg daily lifelong for patients without indications for anticoagulation 8, 9
For patients with chronic atrial fibrillation or other indications for long-term anticoagulation, the American College of Cardiology suggests anticoagulation as per guidelines for atrial fibrillation in patients with prosthetic heart valves 8, 9

The American College of Cardiology recommends echocardiography before discharge to provide a new baseline of transcatheter valve function, and repeat echocardiography at 30 days and then at least annually to monitor for complications of TAVR 9, 10
Periodic ECG monitoring is recommended for detection of asymptomatic atrial fibrillation, with pre-existing atrial fibrillation present in about 25% of patients who undergo TAVR, and new-onset atrial fibrillation after TAVR ranging from <1% to 8.6% 8, 9

The American College of Cardiology suggests careful monitoring for bleeding complications, especially in elderly TAVR patients who often have multiple comorbidities 8, 11
For patients with high bleeding risk, consideration of single antiplatelet therapy rather than dual antiplatelet therapy is recommended if no indication for anticoagulation exists, although this specific recommendation is not directly cited 8, 11